The department of Arterial Hypertension was founded in 1985 and deals with identification and treatment of patients with essential hypertension and symptomatic hypertension.
Main scope of activity in the department of Arterial Hypertension devoted to unraveling mechanisms underlying of development of arterial hypertension, issues of secondary prevention of cardiovascular complications of hypertension. In this connection such modern methods of study are used as 24h monitoring of arterial blood pressure, echocardiography, Dopplerography of carotid arteries, studying of vasomotor reaction of vessels, studying of a functional state of the endothelium, studying of the renal function, studying of the blood lipid spectrum.
In the department also conducted genetics studies aimed to identify gene-candidates for essential hypertension, development of genetic fingerprint associated with risks of cardiovascular diseases, primarily, of essential hypertension.
From 1991 to 1999 the pharmacodynamic effects of more than 10 antihypertensive drugs were studied, the differential approaches to the choice of antihypertensive drugs were developed.
As a result, more than 30 research papers were published, results of the studies were presented at international conferences and workshops, 1 doctoral and 9 Ph.D. thesis were defended, scientific and applied guidance were issued: “Differential treatment of severe hypertension” (1991); “Peripheral vasodilators” (1992); “Beta-blokers in cardiology practice” (1999); 3 methods of hypertension treatment have been patented. Since 2000, the laboratory research interests have been focusing on the problem of cardiovascular remodeling in essential hypertension, with the participation of genetics factors, as well as on the development of adequate methods of drug therapy based on pharmacogenetic aspects. Under the supervision of prof. MR Eliseyeva in 2007, as part of the department of AH the group of molecular-genetic research was organized, since 2008 the department AH was renamed to “AH and molecular-genetic studies”.
Currently in the laboratory of molecular-genetic studies more than 10 candidate-genes of arterial hypertension, coronary heart disease, insulin resistance and cytochrome P450 genes involved in the metabolism of drugs were determined. During the period of 2000-2011the pharmacodynamic effects of more than 10 antihypertensive drugs were studied, the ethnic characteristics of genetic determinants of essential hypertension were defined; the differential approaches to the choice of antihypertensive drugs were developed. According to studies more than 70 scientific articles were published, research results are presented at international conferences and workshops, 2 doctoral and 10 Ph.D.
“Beta-blokers in cardiology practice”; “Angiotensin-converting enzyme inhibitors in cardiology practice”; “Endothelial dysfunction and cardiovascular diseases”, “Pharmacogenetic approaches to therapy of essential hypertension”, “The clinical aspects of symptomatic arterial hypertension”, “The modern principles of diagnosis and treatment of arterial hypertension”, “The use of calcium channel blockers at arterial hypertension”. A monography “The molecular-genetic aspects of arterial hypertension” was published by staff of the department. Currently, in the frames of the research project (2007-2011 years) : ” The value of intergenomic impact on the level of nuclear and mitochondrial polymorphism in the development of essential hypertension in patients Uzbek population” intergenomic interactions being studied, particularly, nuclear and mitochondrial polymorphism to unravel complex picture of the contribution of genetic determinants in the development of EH. The guidelines “Application software Sequencher 4.0 in biomedical practice.” was issued.
For the first time in the republic a National DNA bank of patients with arterial hypertension was developed, the work on the creation of a genetic “fingerprint” of essential hypertension risk was actively conducted, which would be the basis for the development of preventive measures of hypertension and enable individualized therapy, to put into practice the principle of a well-known medicine, formulated more than 200 years ago, by M .I . Mudrov – “treat the patient, not the disease”.